Guselkumab vs Risankizumab for Ulcerative Colitis: Real-World Comparison of Postinduction Outcomes
Clinical Gastroenterology and Hepatology · 2026-09
DOI: 10.1016/j.cgh.2026.09.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-09. Verfasst von Rahul S Dalal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massac…. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: rsdalal@bwh.harvard.edu.
- Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Zitieren
APA
Dalal, R. S., Silvestri, M. E., Kwaning, K. M., Carlin, A. D., Mcclure, E. L., & Allegretti, J. R. (2026). Guselkumab vs Risankizumab for Ulcerative Colitis: Real-World Comparison of Postinduction Outcomes. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.09.018
Vancouver
Dalal RS, Silvestri ME, Kwaning KM, Carlin AD, Mcclure EL, Allegretti JR. Guselkumab vs Risankizumab for Ulcerative Colitis: Real-World Comparison of Postinduction Outcomes. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.09.018
BibTeX
@article{Dalal2026,
author = {Dalal, Rahul S and Silvestri, Mia E and Kwaning, Karen M and Carlin, Alex D and Mcclure, Emma L and Allegretti, Jessica R},
title = {Guselkumab vs Risankizumab for Ulcerative Colitis: Real-World Comparison of Postinduction Outcomes},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
doi = {10.1016/j.cgh.2026.09.018}
}
EUVIMED